Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO phase 3 trial of relugolix versus leuprolide in advanced prostate cancer
NL-OMON50691Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 arms), sponsored by Myovant Sciences. Primary endpoint: Sustained castration rate. Started Jan 2018; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON50691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50691.